Paion UK Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Dosing regimen for sedation with CNS 7056 (Remimazolam) (US 10,342,800) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Process for Preparing 3-[(S)-7-Bromo-2-((2-Oxopropyl)AMINO)-5-Pyridin-2-YL-3H-1,4-Benzodiazepin-3-YL]PROPIONIC Acid Methyl Ester (US 10,414,749) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 13, 2027The maintenance fee for Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiazepine-4-YL]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process (US 9,156,842) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due May 24, 2027The maintenance fee for Short-acting benzodiazepine salts and their polymorphic forms (US 9,193,730) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,777,007 | Short-acting benzodiazepine salts and their polymorphic forms In force · USPTO record | In force | USPTO record | |
| US 9,914,738 | Short-acting benzodiazepine salts and their polymorphic forms In force · USPTO record | In force | USPTO record | |
| US 10,472,365 | Short-acting benzodiazepine salts and their polymorphic forms In force · USPTO record | In force | USPTO record | |
| US 10,961,250 | Short-acting benzodiazepine salts and their polymorphic forms In force · USPTO record | In force | USPTO record | |
| US 8,642,588 | Short-acting benzodiazepine salts and their polymorphic forms In force · USPTO record | In force | USPTO record | |
| US 12,365,684 | Short-acting benzodiazepine salts and their polymorphic forms In force · USPTO record | In force | USPTO record | |
| US 9,512,078 | Process for preparing 3-[(45)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiazepine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process In force · USPTO record | In force | USPTO record | |
| US 10,000,464 | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiazepine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process In force · USPTO record | In force | USPTO record | |
| US 9,737,547 | Dosing regimen for sedation with CNS 7056 (Remimazolam) In force · USPTO record | In force | USPTO record | |
| US 10,052,334 | Dosing regimen for sedation with CNS 7056 (remimazolam) In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 21: 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 3 abandoned · 4 no status recorded